PMID- 29147863
OWN - NLM
STAT- MEDLINE
DCOM- 20190304
LR  - 20190304
IS  - 1573-7373 (Electronic)
IS  - 0167-594X (Linking)
VI  - 136
IP  - 3
DP  - 2018 Feb
TI  - Prognostic relevance of programmed cell death ligand 1 expression in 
      glioblastoma.
PG  - 453-461
LID - 10.1007/s11060-017-2675-6 [doi]
AB  - The aim of this study was to determine the clinicopathological significance of 
      programmed cell death ligand 1 (PD-L1) expression in glioblastoma (GBM). In a 
      retrospective cohort of 115 consecutive patients with GBM, PD-L1 expression was 
      determined using immunohistochemistry (IHC). Membranous and fibrillary PD-L1 
      staining of any intensity in > 5% neoplastic cells and tumour infiltrating immune 
      cells (TIIs) was considered positive staining. In addition, isocitrate 
      dehydrogenase-1 (IDH-1) (R132H) expression and cluster of differentiation 3 
      (CD3)-positive T-cell infiltration were investigated using IHC. 
      O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation assay and 
      fluorescence in situ hybridization (FISH) for the assessment of 1p/19q deletion 
      were performed. Expression of PD-L1 in tumour cells and TIIs was found in 37 
      (32.2%) and 6 (5.2%) patients, respectively. Kaplan-Meier analysis indicated that 
      PD-L1 expression in tumour cells was significantly associated with poor overall 
      survival (OS) (P = 0.017), though multivariate Cox analysis did not confirm this 
      association (hazard ratio 1.204; P = 0.615). PD-L1 expression in TIIs did not 
      correlate with the patient prognosis (P = 0.545). In addition, MGMT methylation 
      and IDH-1 (R132H) expression were associated with a better prognosis (P < 0.001 
      and P = 0.024, respectively). The expression of PD-L1 was associated with 
      CD3-positive T-cell infiltration (P < 0.001), and IDH-1 wild type status 
      (P = 0.008). A deeper insight into PD-L1 expression could help to ensure the 
      success of future immunotherapy in GBM. Our study suggested that PD-L1 target 
      therapy might be beneficial for PD-L1-expressing GBM patients with a poor 
      prognosis.
FAU - Lee, Kyu Sang
AU  - Lee KS
AD  - Department of Pathology, Seoul National University Bundang Hospital, 173-82 
      Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea.
FAU - Lee, Kyoungyul
AU  - Lee K
AD  - Department of Pathology, Kangwon National University Hospital, 156 
      Baengnyeong-ro, Chuncheon-Si, Kangwon-Do, 200-722, Republic of Korea.
FAU - Yun, Sumi
AU  - Yun S
AD  - Department of Diagnostic Pathology, Samkwang Medical Laboratories, 57, Baumoe-ro 
      41-gil, Seocho-gu, Seoul, Republic of Korea.
FAU - Moon, Seyoung
AU  - Moon S
AD  - Department of Pathology, Seoul National University Bundang Hospital, 173-82 
      Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea.
FAU - Park, Yujun
AU  - Park Y
AD  - Department of Pathology, Seoul National University Bundang Hospital, 173-82 
      Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea.
FAU - Han, Jung Ho
AU  - Han JH
AD  - Department of Neurosurgery, Seoul National University Bundang Hospital, 173-82 
      Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea.
FAU - Kim, Chae-Yong
AU  - Kim CY
AD  - Department of Neurosurgery, Seoul National University Bundang Hospital, 173-82 
      Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea.
FAU - Lee, Hye Seung
AU  - Lee HS
AD  - Department of Pathology, Seoul National University Bundang Hospital, 173-82 
      Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea.
FAU - Choe, Gheeyoung
AU  - Choe G
AUID- ORCID: 0000-0001-6547-5603
AD  - Department of Pathology, Seoul National University Bundang Hospital, 173-82 
      Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea. 
      gychoe@snu.ac.kr.
LA  - eng
GR  - 11-2011-021/Seoul National University Bundang Hospital research fund/
PT  - Journal Article
DEP - 20171116
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD274 protein, human)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.1.1.- (DNA Modification Methylases)
RN  - EC 2.1.1.63 (MGMT protein, human)
RN  - EC 6.5.1.- (DNA Repair Enzymes)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - B7-H1 Antigen/*metabolism
MH  - Biomarkers, Tumor/metabolism
MH  - Brain Neoplasms/genetics/*metabolism/mortality/pathology
MH  - DNA Methylation
MH  - DNA Modification Methylases/genetics/metabolism
MH  - DNA Repair Enzymes/genetics/metabolism
MH  - Follow-Up Studies
MH  - Glioblastoma/genetics/*metabolism/mortality/pathology
MH  - Humans
MH  - Middle Aged
MH  - Prognosis
MH  - Promoter Regions, Genetic
MH  - Retrospective Studies
MH  - Tumor Suppressor Proteins/genetics/metabolism
MH  - Young Adult
OTO - NOTNLM
OT  - CD274
OT  - Glioblastoma
OT  - Immunohistochemistry
OT  - Prognosis
OT  - Programmed cell death ligand 1
EDAT- 2017/11/18 06:00
MHDA- 2019/03/05 06:00
CRDT- 2017/11/18 06:00
PHST- 2017/07/02 00:00 [received]
PHST- 2017/11/11 00:00 [accepted]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2019/03/05 06:00 [medline]
PHST- 2017/11/18 06:00 [entrez]
AID - 10.1007/s11060-017-2675-6 [pii]
AID - 10.1007/s11060-017-2675-6 [doi]
PST - ppublish
SO  - J Neurooncol. 2018 Feb;136(3):453-461. doi: 10.1007/s11060-017-2675-6. Epub 2017 
      Nov 16.